Prolonged Air Leak (PAL) Autologous Blood Patch Intervention Trial

Study summary

A postoperative autologous blood patch (ABP) intervention trial for patients who underwent lung resection for cancer to examine its effectiveness in preventing a prolonged air leak. AIM 1: To determine the safety and efficacy of autologous blood patch (ABP) as a means to reduce the rate of prolonged air leak (PAL) after lung cancer resection AIM 2: To prospectively examine variation in morbidity and quality of life between patients with and without a PAL

Ask AI to explain this study

Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedAutologous Blood Patch and Standard of Care (per Physician)

The study team can explain what participation involves.

Who it may be forLung Cancer

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Oct 10, 2025 · Source: ClinicalTrials.gov

Is enrollment open?Enrolling By Invitation

Participation is limited to people invited by the study team.

What kind of study?Not applicable

Interventional

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?Rush University Medical Center

Study sponsor

Study overview

What this study is about

Purpose: Treatment
Study type: Interventional
Phase: Not applicable
Sponsor: Rush University Medical Center
Interventions being studied: Procedure: Autologous Blood Patch; Procedure: Standard of Care (per Physician)

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Treatment approach

Surgery→

Study topics

After surgery (adjuvant)→Survivorship and quality of life→

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

Patients who underwent elective wedge resection, segmentectomy, lobectomy, or bilobectomy for suspected non-small cell lung cancer
Patients that have reviewed and signed the Informed Consent Form, had an opportunity to ask questions, and consent to have their de-identified data included in the study
Patients who have an air leak on the morning of postoperative Day 3
Age ≥18 years old

Reasons someone may not be able to joinExclusion criteria

Patients who undergo pneumonectomy, sleeve lobectomy, chest wall or diaphragm resection, or bilateral procedures.
Age \< 18 years old
Women who are pregnant

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

Rush University Medical CenterChicago, Illinois

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Oct 10, 2025. Always confirm current availability with the study team.

View original record ↗